Rybelsus, Ozempic and Wegovy: One Molecule, Three Products, Three Different Answers
Rybelsus, Ozempic and Wegovy all contain semaglutide from the same manufacturer. Rybelsus is an oral tablet approved for type 2 diabetes at 3 to 14 mg. Ozempic is a weekly injection approved for type 2 diabetes up to 2.0 mg. Wegovy is approved for chronic weight management at up to 2.4 mg, and exists as both a weekly pen and a tablet. The indication, not the molecule, decides whether a plan pays.
The three products side by side
| Field | Rybelsus | Ozempic | Wegovy |
|---|---|---|---|
| Route | Daily tablet | Weekly injection | Weekly injection, and a tablet |
| Approved for | Type 2 diabetes | Type 2 diabetes | Chronic weight management |
| Dose range | 3–14 mg | up to 2.0 mg | up to 2.4 mg; 7.2 mg HD pen |
| Food requirement | Empty stomach, then wait | No required fee | None for the pen |
| Cardiovascular outcomes trial | — | — | SELECT: ~20% MACE reduction |
| Coverage likelihood | High with a diabetes diagnosis | High with a diabetes diagnosis | Lower — many plans exclude obesity drugs |
| Self-pay | Varies | $349 · $499 at 2 mg | $349 pen · $399 HD · $149–$299 tablet |
Self-pay figures read on the manufacturer's published price guide, 4 August 2026.
Why the oral versions need an empty stomach
Semaglutide is a peptide, and peptides are digested. The tablets get around that with SNAC, an absorption enhancer, which is why the labelling specifies taking them on an empty stomach with a small sip of water and waiting before eating or drinking anything else. Absorption falls if that is not followed, and the routine is the real trade-off against a weekly injection.
Read on the manufacturer's published price guide, 4 August 2026.
Which one gets covered
The diabetes products, if you have the diagnosis. Most plans cover diabetes medicines, and a large share still exclude weight-loss drugs outright. That asymmetry — not efficacy — is why so many people end up on a diabetes-indicated product, and why prescribing one for weight alone is off-label and usually uncovered.
What about compounded "oral semaglutide"?
Sublingual and orally disintegrating compounded preparations are none of the three products above. They contain no absorption enhancer studied for this purpose, have no bioavailability data of their own, and no trial. They are also, on the pricing we have seen, frequently the most expensive compounded protocol rather than the cheapest.
Switching between them
These are not interchangeable at equivalent doses, and switching is a prescriber's decision. The doses do not map across products — 14 mg oral is not "more" than 2.4 mg injected, because the routes have different bioavailability. Anyone converting between them by arithmetic is doing something the labelling does not support.
What each one has behind it
| Product | Pivotal evidence | What it establishes |
|---|---|---|
| Wegovy pen | STEP-1: 14.9% mean loss at 68 weeks | Weight management at 2.4 mg |
| Wegovy pen | SELECT: ~20% MACE reduction | Cardiovascular event reduction |
| Wegovy tablet | Oral programme trials | Weight management via the oral route |
| Ozempic | SUSTAIN programme | Glycaemic control in type 2 diabetes |
| Rybelsus | PIONEER programme | Glycaemic control via the oral route |
SELECT is the trial that separates semaglutide from tirzepatide on cardiovascular evidence, and it studied the injection.
The practical questions, in order
- Do I have a type 2 diabetes diagnosis? If yes, the diabetes-indicated products are far more likely to be covered.
- Is my goal weight management? Then Wegovy is the approval, and coverage is the obstacle rather than the prescription.
- Can I follow a daily empty-stomach routine? If not, the tablet's advantage disappears.
- Is cardiovascular risk part of the picture? SELECT applies to the injection in a specific population.
What this page does not settle
- Which is right for you. Indication, comorbidities and coverage decide that with a prescriber.
- Whether oral and injected semaglutide are equivalent at any dose. They were trialled separately, and no head-to-head establishes equivalence.
- Anything about compounded preparations. None of these trials studied one.
Shown in tenths of a milligram for the injections (24 = 2.4 mg) and milligrams for the tablets. Oral and injected doses are not comparable numbers — the routes have different bioavailability.
The naming problem, stated plainly
One molecule, five presentations, three brand names and two indications. It is genuinely confusing, and the confusion has consequences: people ask for the wrong product, get denied for the wrong reason, or compare a price for one against efficacy data from another.
The rule that resolves most of it: the indication on the box decides coverage, and the dose decides which trial applies. The molecule decides almost nothing on its own.
What the compounded market did to this picture
Compounded semaglutide is sold without any of these brand names, at doses set by the provider rather than by an approval, sometimes in sublingual forms with no bioavailability data. It sits outside the table above entirely — not as a fourth product, but as a category with no trial of its own.
That is not an argument against it where a prescriber has documented a clinical reason. It is an argument against reading any figure from this page as though it described one.
Common questions
Can my doctor prescribe Ozempic for weight loss?
It can be prescribed off-label, and off-label prescribing is lawful and common. Two things follow: your plan is unlikely to cover it for that purpose, and Ozempic's approved maximum of 2.0 mg is below the 2.4 mg dose the weight-management trial studied. So it is possible, generally uncovered, and not the product the headline figure came from.
Is the tablet as good as the injection?
They were studied separately rather than head to head, so no trial establishes equivalence at any pair of doses. The tablet has a real advantage for people who will not inject, and a real requirement: an empty stomach and a wait before eating, every day. Missing that reduces absorption.
Why is Wegovy harder to get covered than Ozempic?
Because most plans cover diabetes medicines and a large share still exclude obesity medicines. That is a purchasing decision made when the benefit was bought, not a judgement about the drug, and it is why a diabetes diagnosis changes the coverage answer so completely.
What is Wegovy HD?
A higher-dose weekly pen at 7.2 mg, priced at $399 a month self-pay, for people whose response at 2.4 mg was inadequate. It is not a faster route for someone starting treatment, and the widely quoted 14.9% figure was collected at 2.4 mg rather than at 7.2.